TNFSF11 and periodontal disorder: In the previously reported study results, the secoiridoid glucosides-based compound swertiamarin demonstrated the inhibitory effect of RANKL-induced inflammation and osteoclast differentiation, and suggested the possibility of a secoiridoid glucosides-based compound for the treatment of periodontal disease [32].